Medical technology company Intuitive Surgical (NASDAQ: ISRG) beat Wall Street’s revenue expectations in Q3 2026, with sales up 21.7% year on year to $3.05 billion. Its non-GAAP profit of $3 per share was 13.6% above analysts’ consensus estimates.

Is now the time to buy ISRG? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Intuitive Surgical delivered third quarter results that exceeded Wall Street’s expectations for both revenue and adjusted earnings per share. However, the market reacted negatively, with shares trading down sharply after the report. Management attributed the quarter’s topline growth to robust global demand for da Vinci and Ion systems, especially in benign procedures and international markets. CEO David Rosa highlighted, “Da Vinci system placements increased 28% worldwide with da Vinci 5 and SP accounting for 65% of global placements.” Despite this momentum, the company acknowledged that a significant decline in GAAP operating margin—primarily due to a $450 million litigation settlement—weighed on profitability. Non-GAAP operating margin, however, remained strong, as increased R&D and prototype spending supported new technology rollouts and international expansion.

Looking forward, management’s guidance centers on expanding access through continued product innovation, strategic price reductions, and international expansion. The company is prioritizing investments in AI capabilities, new system features, and broader clinical adoption, particularly for benign and cardiac procedures. CFO Jamie Samath noted that upcoming price changes are designed to “drive elasticity” and broaden the addressable market, while ongoing R&D spend is expected to remain above sales and marketing growth rates. Management acknowledged potential headwinds related to lower U.S. government health program enrollments and evolving reimbursement environments in key overseas markets.

Key insights from management’s remarks

Management identified global da Vinci adoption, procedure growth in new clinical areas, and strategic pricing actions as primary drivers of the quarter's performance, but noted that margin compression and upcoming pricing headwinds shaped sentiment.

• International procedure expansion: Growth was strongest outside the U.S., with total and da Vinci procedures up 20%. Europe and Asia saw substantial contributions from benign surgeries such as hernia repair and cholecystectomy, reflecting increased clinical acceptance and local reimbursement progress.
• Benign procedure focus: Management emphasized a strategic pivot toward high-volume benign procedures, supported by new pricing actions and clinical studies showing favorable outcomes for da Vinci versus traditional approaches. These efforts aim to reduce barriers to adoption and expand Intuitive’s total addressable market.
• Pricing actions and elasticity: The company finalized price reductions for select instruments in benign procedures and extended use policies, with an expected 3-5% revenue per procedure headwind once fully implemented. Management believes these actions will increase procedure volumes over time, citing evidence of price sensitivity and elasticity in targeted segments.
• Innovation in product portfolio: Uptake of da Vinci 5, SP, and Ion platforms accelerated, with da Vinci 5 now installed at over 2,000 sites. New features such as Force Feedback instruments are available, while AI-enabled workflow enhancements, including voice-activated interfaces and automated fourth arm control, are currently in development and are expected to influence procedure mix and utilization in the future.
• Margin compression and investment: GAAP operating margin declined year-on-year, primarily due to a $450 million litigation settlement, with additional pressure from increased R&D and prototype spending to support new technology rollouts and international expansion. The company sees these investments as critical to sustaining long-term growth despite near-term margin pressure. Non-GAAP operating margin remained strong.

Drivers of future performance

Intuitive Surgical’s outlook is driven by international expansion, adoption of new technology, and the impact of strategic pricing, but offset by margin headwinds and evolving reimbursement.

• International and benign procedure growth: Expansion into additional countries and broader benign procedure adoption are expected to drive double-digit procedure growth. Management is particularly focused on supporting local market access, regulatory approvals, and clinical validation in Europe and Asia.
• Pricing and margin headwinds: Upcoming instrument price reductions and lower prices in China are forecast to reduce revenue per procedure, creating headwinds for gross and operating margins. Management plans to offset some impact through ongoing cost reductions and increased adoption of higher-margin products, but expects margin pressure to persist as these changes phase in.
• AI and technology investments: Continued R&D investment in artificial intelligence, advanced imaging, and telepresence features is intended to differentiate Intuitive’s platforms and support future revenue per procedure. Management sees these innovations as essential for expanding into new indications and sustaining long-term growth, but acknowledged that higher near-term investment will weigh on profitability.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will be focused on (1) the pace of international market expansion and benign procedure adoption, (2) the rollout and uptake of new pricing strategies and instrument use policies, and (3) the impact of AI-driven product enhancements and expanded indications for da Vinci and Ion systems. Progress in reimbursement and regulatory approvals, particularly in Asia and Europe, will also be critical markers of execution.

Intuitive Surgical currently trades at $405.49, down from $438 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.